Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Alternative dosing guidelines to improve outcomes in childhood tuberculosis: a mathematical modelling study.

Radtke KK, Dooley KE, Dodd PJ, Garcia-Prats AJ, McKenna L, Hesseling AC, Savic RM.

Lancet Child Adolesc Health. 2019 Sep;3(9):636-645. doi: 10.1016/S2352-4642(19)30196-8. Epub 2019 Jul 16.

PMID:
31324596
2.

Advancing the development of new tuberculosis treatment regimens: The essential role of translational and clinical pharmacology and microbiology.

Dooley KE, Hanna D, Mave V, Eisenach K, Savic RM.

PLoS Med. 2019 Jul 5;16(7):e1002842. doi: 10.1371/journal.pmed.1002842. eCollection 2019 Jul. No abstract available.

3.

Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies.

Garcia-Prats AJ, Schaaf HS, Draper HR, Garcia-Cremades M, Winckler J, Wiesner L, Hesseling AC, Savic RM.

PLoS Med. 2019 Apr 30;16(4):e1002789. doi: 10.1371/journal.pmed.1002789. eCollection 2019 Apr.

4.

Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization.

Strydom N, Gupta SV, Fox WS, Via LE, Bang H, Lee M, Eum S, Shim T, Barry CE 3rd, Zimmerman M, Dartois V, Savic RM.

PLoS Med. 2019 Apr 2;16(4):e1002773. doi: 10.1371/journal.pmed.1002773. eCollection 2019 Apr.

5.

Fluoroquinolone Efficacy against Tuberculosis Is Driven by Penetration into Lesions and Activity against Resident Bacterial Populations.

Sarathy J, Blanc L, Alvarez-Cabrera N, O'Brien P, Dias-Freedman I, Mina M, Zimmerman M, Kaya F, Ho Liang HP, Prideaux B, Dietzold J, Salgame P, Savic RM, Linderman J, Kirschner D, Pienaar E, Dartois V.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e02516-18. doi: 10.1128/AAC.02516-18. Print 2019 May.

6.

Modeling Prevention of Malaria and Selection of Drug Resistance with Different Dosing Schedules of Dihydroartemisinin-Piperaquine Preventive Therapy during Pregnancy in Uganda.

Wallender E, Zhang N, Conrad M, Kakuru A, Muhindo M, Tumwebaze P, Kajubi R, Mota D, Legac J, Jagannathan P, Havlir D, Kamya M, Dorsey G, Aweeka F, Rosenthal PJ, Savic RM.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01393-18. doi: 10.1128/AAC.01393-18. Print 2019 Feb.

7.

Publisher Correction: A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis.

Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, Hermann D, Wallis RS, Johnson JL, Lienhardt C, Savic RM.

Nat Med. 2019 Jan;25(1):190. doi: 10.1038/s41591-018-0294-1.

PMID:
30429542
8.

High-resolution mapping of fluoroquinolones in TB rabbit lesions reveals specific distribution in immune cell types.

Blanc L, Daudelin IB, Podell BK, Chen PY, Zimmerman M, Martinot AJ, Savic RM, Prideaux B, Dartois V.

Elife. 2018 Nov 14;7. pii: e41115. doi: 10.7554/eLife.41115.

9.

A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis.

Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, Hermann D, Wallis RS, Johnson JL, Lienhardt C, Savic RM.

Nat Med. 2018 Nov;24(11):1708-1715. doi: 10.1038/s41591-018-0224-2. Epub 2018 Nov 5. Erratum in: Nat Med. 2019 Jan;25(1):190.

10.

Population Pharmacokinetics and Pharmacodynamics of Disulfiram on Inducing Latent HIV-1 Transcription in a Phase IIb Trial.

Lee SA, Elliott JH, McMahon J, Hartogenesis W, Bumpus NN, Lifson JD, Gorelick RJ, Bacchetti P, Deeks SG, Lewin SR, Savic RM.

Clin Pharmacol Ther. 2019 Mar;105(3):692-702. doi: 10.1002/cpt.1220. Epub 2018 Oct 9.

PMID:
30137649
11.

Impact of immunopathology on the antituberculous activity of pyrazinamide.

Blanc L, Sarathy JP, Alvarez Cabrera N, O'Brien P, Dias-Freedman I, Mina M, Sacchettini J, Savic RM, Gengenbacher M, Podell BK, Prideaux B, Ioerger T, Dick T, Dartois V.

J Exp Med. 2018 Aug 6;215(8):1975-1986. doi: 10.1084/jem.20180518. Epub 2018 Jul 17.

12.

Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data.

Rifat D, Prideaux B, Savic RM, Urbanowski ME, Parsons TL, Luna B, Marzinke MA, Ordonez AA, DeMarco VP, Jain SK, Dartois V, Bishai WR, Dooley KE.

Sci Transl Med. 2018 Apr 4;10(435). pii: eaai7786. doi: 10.1126/scitranslmed.aai7786.

13.

Intermittent Preventive Treatment for Malaria in Pregnancy: Optimization of Target Concentrations of Dihydroartemisinin-Piperaquine.

Savic RM, Jagannathan P, Kajubi R, Huang L, Zhang N, Were M, Kakuru A, Muhindo MK, Mwebaza N, Wallender E, Clark TD, Opira B, Kamya M, Havlir DV, Rosenthal PJ, Dorsey G, Aweeka FT.

Clin Infect Dis. 2018 Sep 14;67(7):1079-1088. doi: 10.1093/cid/ciy218.

14.

Predicting Optimal Dihydroartemisinin-Piperaquine Regimens to Prevent Malaria During Pregnancy for Human Immunodeficiency Virus-Infected Women Receiving Efavirenz.

Wallender E, Vucicevic K, Jagannathan P, Huang L, Natureeba P, Kakuru A, Muhindo M, Nakalembe M, Havlir D, Kamya M, Aweeka F, Dorsey G, Rosenthal PJ, Savic RM.

J Infect Dis. 2018 Mar 5;217(6):964-972. doi: 10.1093/infdis/jix660.

15.

Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose Modifications.

Guiastrennec B, Ramachandran G, Karlsson MO, Kumar AKH, Bhavani PK, Gangadevi NP, Swaminathan S, Gupta A, Dooley KE, Savic RM.

Clin Pharmacol Ther. 2018 Oct;104(4):733-741. doi: 10.1002/cpt.987. Epub 2018 Feb 2.

16.

Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis.

Denti P, Garcia-Prats AJ, Draper HR, Wiesner L, Winckler J, Thee S, Dooley KE, Savic RM, McIlleron HM, Schaaf HS, Hesseling AC.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01521-17. doi: 10.1128/AAC.01521-17. Print 2018 Feb.

17.

Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.

Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L.

Breast Cancer Res. 2017 Sep 11;19(1):107. doi: 10.1186/s13058-017-0896-4.

18.

New Paradigm for Translational Modeling to Predict Long-term Tuberculosis Treatment Response.

Bartelink IH, Zhang N, Keizer RJ, Strydom N, Converse PJ, Dooley KE, Nuermberger EL, Savic RM.

Clin Transl Sci. 2017 Sep;10(5):366-379. doi: 10.1111/cts.12472. Epub 2017 May 31.

19.

Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis.

Savic RM, Novakovic AM, Ekblom M, Munafo A, Karlsson MO.

Clin Pharmacokinet. 2017 Oct;56(10):1245-1253. doi: 10.1007/s40262-017-0516-6.

20.

Importance of Drug Pharmacokinetics at the Site of Action.

Rizk ML, Zou L, Savic RM, Dooley KE.

Clin Transl Sci. 2017 May;10(3):133-142. doi: 10.1111/cts.12448. Epub 2017 Feb 3. Review. No abstract available.

21.

Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials.

Savic RM, Weiner M, MacKenzie WR, Engle M, Whitworth WC, Johnson JL, Nsubuga P, Nahid P, Nguyen NV, Peloquin CA, Dooley KE, Dorman SE; Tuberculosis Trials Consortium of the Centers for Disease Control and Prevention.

Clin Pharmacol Ther. 2017 Aug;102(2):321-331. doi: 10.1002/cpt.634. Epub 2017 Mar 2.

22.

Xpert MTB/RIF Assay Shows Faster Clearance of Mycobacterium tuberculosis DNA with Higher Levels of Rifapentine Exposure.

Jayakumar A, Savic RM, Everett CK, Benator D, Alland D, Heilig CM, Weiner M, Friedrich SO, Martinson NA, Kerrigan A, Zamudio C, Goldberg SV, Whitworth WC, Davis JL, Nahid P.

J Clin Microbiol. 2016 Dec;54(12):3028-3033. Epub 2016 Oct 12.

23.

Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis.

Bartelink IH, Lalmohamed A, van Reij EM, Dvorak CC, Savic RM, Zwaveling J, Bredius RG, Egberts AC, Bierings M, Kletzel M, Shaw PJ, Nath CE, Hempel G, Ansari M, Krajinovic M, Théorêt Y, Duval M, Keizer RJ, Bittencourt H, Hassan M, Güngör T, Wynn RF, Veys P, Cuvelier GD, Marktel S, Chiesa R, Cowan MJ, Slatter MA, Stricherz MK, Jennissen C, Long-Boyle JR, Boelens JJ.

Lancet Haematol. 2016 Nov;3(11):e526-e536. doi: 10.1016/S2352-3026(16)30114-4. Epub 2016 Oct 13.

24.

A Longitudinal HbA1c Model Elucidates Genes Linked to Disease Progression on Metformin.

Goswami S, Yee SW, Xu F, Sridhar SB, Mosley JD, Takahashi A, Kubo M, Maeda S, Davis RL, Roden DM, Hedderson MM, Giacomini KM, Savic RM.

Clin Pharmacol Ther. 2016 Nov;100(5):537-547. doi: 10.1002/cpt.428. Epub 2016 Sep 23.

25.

A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis.

Conde MB, Mello FC, Duarte RS, Cavalcante SC, Rolla V, Dalcolmo M, Loredo C, Durovni B, Armstrong DT, Efron A, Barnes GL, Marzinke MA, Savic RM, Dooley KE, Cohn S, Moulton LH, Chaisson RE, Dorman SE.

PLoS One. 2016 May 9;11(5):e0154778. doi: 10.1371/journal.pone.0154778. eCollection 2016.

26.

The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin.

Hibma JE, Zur AA, Castro RA, Wittwer MB, Keizer RJ, Yee SW, Goswami S, Stocker SL, Zhang X, Huang Y, Brett CM, Savic RM, Giacomini KM.

Clin Pharmacokinet. 2016 Jun;55(6):711-21. doi: 10.1007/s40262-015-0346-3.

27.

Pediatric tuberculous meningitis: Model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children.

Savic RM, Ruslami R, Hibma JE, Hesseling A, Ramachandran G, Ganiem AR, Swaminathan S, McIlleron H, Gupta A, Thakur K, van Crevel R, Aarnoutse R, Dooley KE.

Clin Pharmacol Ther. 2015 Dec;98(6):622-9. doi: 10.1002/cpt.202. Epub 2015 Oct 22.

28.

Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers.

Dooley KE, Savic RM, Park JG, Cramer Y, Hafner R, Hogg E, Janik J, Marzinke MA, Patterson K, Benson CA, Hovind L, Dorman SE, Haas DW; ACTG A5311 Study Team.

Antimicrob Agents Chemother. 2015;59(6):3399-405. doi: 10.1128/AAC.05128-14. Epub 2015 Mar 30.

29.

The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda.

Bartelink IH, Savic RM, Dorsey G, Ruel T, Gingrich D, Scherpbier HJ, Capparelli E, Jullien V, Young SL, Achan J, Plenty A, Charlebois E, Kamya M, Havlir D, Aweeka F.

Pediatr Infect Dis J. 2015 Mar;34(3):e63-70. doi: 10.1097/INF.0000000000000603.

30.

Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.

Dorman SE, Savic RM, Goldberg S, Stout JE, Schluger N, Muzanyi G, Johnson JL, Nahid P, Hecker EJ, Heilig CM, Bozeman L, Feng PJ, Moro RN, MacKenzie W, Dooley KE, Nuermberger EL, Vernon A, Weiner M; Tuberculosis Trials Consortium.

Am J Respir Crit Care Med. 2015 Feb 1;191(3):333-43. doi: 10.1164/rccm.201410-1843OC. Erratum in: Am J Respir Crit Care Med. 2015 May 15;191(10):1210.

31.

Designing drug trials: considerations for pregnant women.

Sheffield JS, Siegel D, Mirochnick M, Heine RP, Nguyen C, Bergman KL, Savic RM, Long J, Dooley KE, Nesin M.

Clin Infect Dis. 2014 Dec 15;59 Suppl 7:S437-44. doi: 10.1093/cid/ciu709.

32.

Impact of adherence and anthropometric characteristics on nevirapine pharmacokinetics and exposure among HIV-infected Kenyan children.

Vreeman RC, Nyandiko WM, Liechty EA, Busakhala N, Bartelink IH, Savic RM, Scanlon ML, Ayaya SO, Blaschke TF.

J Acquir Immune Defic Syndr. 2014 Nov 1;67(3):277-86. doi: 10.1097/QAI.0000000000000300.

PMID:
25140906
33.

Rifapentine Pharmacokinetics and Tolerability in Children and Adults Treated Once Weekly With Rifapentine and Isoniazid for Latent Tuberculosis Infection.

Weiner M, Savic RM, Kenzie WR, Wing D, Peloquin CA, Engle M, Bliven E, Prihoda TJ, Gelfond JA, Scott NA, Abdel-Rahman SM, Kearns GL, Burman WJ, Sterling TR, Villarino ME; Tuberculosis Trials Consortium PREVENT TB Pharmacokinetic Group.

J Pediatric Infect Dis Soc. 2014 Jun;3(2):132-45. doi: 10.1093/jpids/pit077. Epub 2014 Jan 16.

PMID:
26625366
34.

Genetic variants in transcription factors are associated with the pharmacokinetics and pharmacodynamics of metformin.

Goswami S, Yee SW, Stocker S, Mosley JD, Kubo M, Castro R, Mefford JA, Wen C, Liang X, Witte J, Brett C, Maeda S, Simpson MD, Hedderson MM, Davis RL, Roden DM, Giacomini KM, Savic RM.

Clin Pharmacol Ther. 2014 Sep;96(3):370-9. doi: 10.1038/clpt.2014.109. Epub 2014 May 22. Erratum in: Clin Pharmacol Ther. 2014 Nov;96(5):626. Clin Pharmacol Ther. 2014 Nov;96(5):626.

35.

Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability.

Savic RM, Lu Y, Bliven-Sizemore E, Weiner M, Nuermberger E, Burman W, Dorman SE, Dooley KE.

Antimicrob Agents Chemother. 2014 Jun;58(6):3035-42. doi: 10.1128/AAC.01918-13. Epub 2014 Mar 10.

36.

Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda.

Bartelink IH, Savic RM, Mwesigwa J, Achan J, Clark T, Plenty A, Charlebois E, Kamya M, Young SL, Gandhi M, Havlir D, Cohan D, Aweeka F.

J Clin Pharmacol. 2014 Feb;54(2):121-32. doi: 10.1002/jcph.167. Epub 2013 Sep 21.

37.

Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation.

Savic RM, Cowan MJ, Dvorak CC, Pai SY, Pereira L, Bartelink IH, Boelens JJ, Bredius RG, Wynn RF, Cuvelier GD, Shaw PJ, Slatter MA, Long-Boyle J.

Biol Blood Marrow Transplant. 2013 Nov;19(11):1608-14. doi: 10.1016/j.bbmt.2013.08.014. Epub 2013 Sep 9.

38.

Reduced renal clearance of cefotaxime in asians with a low-frequency polymorphism of OAT3 (SLC22A8).

Yee SW, Nguyen AN, Brown C, Savic RM, Zhang Y, Castro RA, Cropp CD, Choi JH, Singh D, Tahara H, Stocker SL, Huang Y, Brett CM, Giacomini KM.

J Pharm Sci. 2013 Sep;102(9):3451-7. doi: 10.1002/jps.23581. Epub 2013 May 6.

39.

Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.

Savic RM, Barrail-Tran A, Duval X, Nembot G, Panhard X, Descamps D, Verstuyft C, Vrijens B, Taburet AM, Goujard C, Mentré F; ANRS 134–COPHAR 3 Study Group.

Clin Pharmacol Ther. 2012 Nov;92(5):575-83. doi: 10.1038/clpt.2012.137. Epub 2012 Oct 3.

40.

Standard Error of Empirical Bayes Estimate in NONMEM® VI.

Kang D, Bae KS, Houk BE, Savic RM, Karlsson MO.

Korean J Physiol Pharmacol. 2012 Apr;16(2):97-106. doi: 10.4196/kjpp.2012.16.2.97. Epub 2012 Apr 24.

41.

Analysis of exposure-response of CI-945 in patients with epilepsy: application of novel mixed hidden Markov modeling methodology.

Delattre M, Savic RM, Miller R, Karlsson MO, Lavielle M.

J Pharmacokinet Pharmacodyn. 2012 Jun;39(3):263-71. doi: 10.1007/s10928-012-9248-2. Epub 2012 Apr 29.

PMID:
22544471
42.

The pharmacokinetics of oxypurinol in people with gout.

Stocker SL, McLachlan AJ, Savic RM, Kirkpatrick CM, Graham GG, Williams KM, Day RO.

Br J Clin Pharmacol. 2012 Sep;74(3):477-89. doi: 10.1111/j.1365-2125.2012.04207.x.

43.

Two bootstrapping routines for obtaining imprecision estimates for nonparametric parameter distributions in nonlinear mixed effects models.

Baverel PG, Savic RM, Karlsson MO.

J Pharmacokinet Pharmacodyn. 2011 Feb;38(1):63-82. doi: 10.1007/s10928-010-9177-x. Epub 2010 Nov 13.

PMID:
21076858
44.

Implementation and evaluation of the SAEM algorithm for longitudinal ordered categorical data with an illustration in pharmacokinetics-pharmacodynamics.

Savic RM, Mentré F, Lavielle M.

AAPS J. 2011 Mar;13(1):44-53. doi: 10.1208/s12248-010-9238-5. Epub 2010 Nov 11.

45.

Evaluation of an extended grid method for estimation using nonparametric distributions.

Savic RM, Karlsson MO.

AAPS J. 2009 Sep;11(3):615-27. doi: 10.1208/s12248-009-9138-8.

46.

Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions.

Savic RM, Karlsson MO.

AAPS J. 2009 Sep;11(3):558-69. doi: 10.1208/s12248-009-9133-0. Epub 2009 Aug 1.

47.

Evaluation of the nonparametric estimation method in NONMEM VI: application to real data.

Baverel PG, Savic RM, Wilkins JJ, Karlsson MO.

J Pharmacokinet Pharmacodyn. 2009 Aug;36(4):297-315. doi: 10.1007/s10928-009-9122-z. Epub 2009 Jul 2.

PMID:
19572188
48.

Semiparametric distributions with estimated shape parameters.

Petersson KJ, Hanze E, Savic RM, Karlsson MO.

Pharm Res. 2009 Sep;26(9):2174-85. doi: 10.1007/s11095-009-9931-1. Epub 2009 Jul 1.

PMID:
19568693
49.
50.

Evaluation of the nonparametric estimation method in NONMEM VI.

Savic RM, Kjellsson MC, Karlsson MO.

Eur J Pharm Sci. 2009 Apr 11;37(1):27-35. doi: 10.1016/j.ejps.2008.12.014. Epub 2008 Dec 30.

PMID:
19159684

Supplemental Content

Loading ...
Support Center